Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado lessened its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 273,602 shares of the biopharmaceutical company's stock after selling 6,320 shares during the period. Public Employees Retirement Association of Colorado's holdings in Bristol-Myers Squibb were worth $15,475,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Morse Asset Management Inc boosted its position in shares of Bristol-Myers Squibb by 25.0% during the 3rd quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock worth $517,000 after purchasing an additional 2,000 shares during the period. Tudor Financial Inc. acquired a new position in Bristol-Myers Squibb during the third quarter worth $250,000. Pine Valley Investments Ltd Liability Co boosted its position in shares of Bristol-Myers Squibb by 1.3% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock worth $2,323,000 after buying an additional 575 shares during the period. World Investment Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 18.7% in the third quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock valued at $2,282,000 after buying an additional 6,954 shares in the last quarter. Finally, Arvest Bank Trust Division purchased a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at $1,724,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Up 1.9 %

Shares of NYSE BMY traded up $0.95 during mid-day trading on Friday, reaching $50.56. The company had a trading volume of 14,165,424 shares, compared to its average volume of 12,978,437. The firm has a 50 day simple moving average of $55.83 and a two-hundred day simple moving average of $56.39. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The stock has a market cap of $102.89 billion, a P/E ratio of -11.44, a PEG ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the company posted ($4.40) earnings per share. The business's quarterly revenue was down 5.6% compared to the same quarter last year. Sell-side analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.91%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.09% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on BMY shares. Argus raised Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Citigroup increased their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Finally, Jefferies Financial Group reduced their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.